Before You Commit Capital: How to Pressure-Test Commercial Viability in Pharma
A strong scientific story gets a lot of capital decisions further than it should.
Good efficacy data, a clean safety profile, a credible regulatory pathway. All of that can be true, and the product can still fail commercially, because nobody pressure-tested whether the market will actually pay for it, at the volume and price the business case assumes.
Commercial viability and technical viability are not the same question. A product can be manufacturable, approvable, and still commercially unviable, if reimbursement is unlikely, the addressable population is smaller than assumed, or the competitive landscape shifts before launch. Capital gets committed on the strength of the first question far more often than the second gets asked properly.
This article sets out what a commercial viability analysis actually needs to test, and where the assumptions behind most business cases tend to break.
What commercial viability analysis actually tests
A credible commercial viability assessment goes well beyond a market size slide. It has to test whether the specific product, at the specific price point the business case assumes, can actually capture a defensible share of that market within a realistic timeframe.
That means working through the reimbursement and pricing pathway in the target markets, not just assuming a headline price will hold. It means testing the addressable population against realistic diagnosis and treatment rates, not the epidemiological ceiling. It means mapping the competitive landscape as it will look at launch, not as it looks today, because pipelines move and exclusivity windows close.
None of this replaces the scientific and regulatory workstreams. It sits alongside them, and it is the workstream most likely to be under-resourced, because it does not have a regulatory deadline forcing it to happen.
What a commercial viability analysis should cover
• Reimbursement pathway and pricing precedent in each target market, not a single assumed price point
• Addressable population based on realistic diagnosis and treatment rates, not epidemiological prevalence alone
• Competitive landscape at expected launch date, including pipeline products not yet approved
• Cost of goods and margin sensitivity at realistic volumes, not best-case manufacturing scale
• Distribution and market access routes in each target geography, and the barriers specific to each
Where the assumptions usually break
Most flawed business cases are not built on bad data. They are built on optimistic interpretation of reasonable data, compounded across several assumptions until the final number bears little resemblance to what is achievable.
Peak sales projections are the most common failure point. They are frequently built on the full epidemiological population, with penetration rates borrowed from a best-in-class comparator that took a decade to reach that share, compressed into year three or four of the model. Reimbursement is often assumed rather than tested, particularly in markets where a new health technology assessment body or payer framework has recently changed the goalposts.
Cost of goods is the other quiet killer. Manufacturing economics that look reasonable at commercial scale can look very different in the first two or three years of launch, when volumes are lower and the supply chain has not yet matured. A margin that works at steady state can be underwater during ramp-up, and few business cases model that transition explicitly.
TDP's commercial viability analysis pressure-tests the assumptions behind your business case before capital is committed, not after.
Talk to us about stress-testing your commercial case
The gap between technical and commercial diligence
Most pharma businesses are genuinely rigorous about technical and regulatory diligence. CMC packages get stress-tested, clinical data gets independently reviewed, regulatory strategy gets challenged by people who have sat across the table from the agencies in question. That rigour exists because the consequences of getting it wrong are well understood and visible early, a rejected filing, a failed inspection, a clinical hold.
Commercial diligence rarely gets the same scrutiny, because the consequences of getting it wrong take longer to surface. A product can clear every regulatory and manufacturing hurdle and still underperform commercially for two or three years before anyone can say definitively that the original business case was wrong. By then the capital is spent, the manufacturing capacity is built, and the options for correcting course are far more limited than they would have been before launch.
Closing that gap does not mean applying the same processes used for technical diligence to commercial questions. It means giving the commercial case the same willingness to be proven wrong that the technical case already gets, before the decision it supports becomes difficult to reverse.
When you actually need this
1. Before a fundraising round. Investors will run their own commercial diligence. Knowing where your assumptions are strong and where they are exposed before that conversation starts puts you in a far stronger negotiating position.
2. Before a licensing or partnering decision. Whether you are licensing in or out, the value of the deal rests entirely on commercial assumptions that both sides need to be able to defend, not just agree on in principle.
3. Before committing capital to a new market. Regulatory approval in a new geography does not guarantee commercial viability there. Reimbursement frameworks, competitive dynamics, and pricing precedent vary enough that a viable product in one market can be commercially marginal in another.
4. Before a major manufacturing or capacity investment. Committing capital to scale up production ahead of demand that may not materialise at the assumed price point is one of the more expensive mistakes a pharma business can make.
5. When the board is being asked to sign off on an assumption nobody has independently tested. If the commercial case has only ever been reviewed by the team that built it, that is itself a signal worth acting on.
6. Before a major strategic pivot. Shifting target indication, moving from a niche to a broader population, or repositioning around a new competitive set all reset the commercial assumptions the original business case was built on. Treating the new direction as commercially validated by association with the old one is a common and avoidable error.
What a rapid, structured assessment actually delivers
The value of commercial viability analysis is proportional to how honestly it is done. An assessment built to validate a decision that has already been made is not worth commissioning. An assessment built to genuinely stress-test the case, including the possibility that it does not hold up, is what protects the capital being committed.
Done properly, this does not need to be a slow process. A structured assessment can be built around the specific decision in front of you, focused on the assumptions that actually drive the outcome, rather than a generic market report that restates publicly available data back to you at length.
The output should be usable directly in the decision it was commissioned for: a board paper, an investor conversation, a licensing negotiation, not a document that sits alongside the decision without actually informing it.
Speed matters here in a way it does not always in technical diligence. Capital decisions usually have a deadline, a board meeting, a term sheet expiry, a manufacturing commitment that has to be made before a certain date, and a commercial assessment that arrives after the decision has already been made informally is worth far less than one that arrives in time to actually change it.
Questions worth asking before you commit capital
• Has the reimbursement pathway been tested against current payer precedent, or assumed from an older comparator?
• Does the peak sales model account for realistic ramp-up, or does it jump straight to steady-state penetration?
• Has the competitive landscape been mapped as it will look at launch, including products still in development?
• Does the cost of goods model reflect launch-phase volumes, or only mature commercial scale?
• Has anyone outside the team that built the business case been asked to actively try to break it?
TDP delivers rapid, structured commercial viability due diligence built for speed and decision-readiness, not generic market reporting.
Get in touch before your next capital decision
Test it before you commit, not after
A good scientific and regulatory story earns a product the right to be commercially assessed properly. It does not substitute for that assessment.
The businesses that avoid expensive capital mistakes are not the ones with the most optimistic commercial case. They are the ones willing to have that case genuinely tested before the money moves, by someone whose job is to find the weak assumption, not confirm the one already on the slide.
If the last independent look at your commercial case was more than a funding round or a major milestone ago, that alone is worth treating as a prompt to revisit it.